title: Efficacy of vitrectomy with triamcinolone assistance versus internal limiting membrane peeling for highly myopic macular hole retinal detachment.
abstract: OBJECTIVE
  To compare the outcomes of pars plana vitrectomy (PPV) with or without the adjuvant surgical procedures: triamcinolone acetonide (TA) assistance and/or internal limiting membrane (ILM) peeling for the treatment of highly myopic macular hole retinal detachment (MHRD).
  
  
  METHODS
  Case-control study.
  
  
  METHODS
  Pars plana vitrectomy combined with 2 kinds of adjuvant surgical procedures were used on 96 highly myopic eyes with MHRD. These eyes were assigned to 4 groups randomly: Group 1, non-TA-assisted PPV and without ILM peeling; Group 2, non-TA-assisted PPV with ILM peeling; Group 3, TA-assisted PPV and without ILM peeling; Group 4, TA-assisted PPV with ILM peeling. Anatomical reattachment of the retina, macular hole closure, and best-corrected visual acuity were measured.
  
  
  RESULTS
  The rates of both retinal reattachment and macular hole closure were higher in Group 2 (84.0 and 44.0%) and Group 3 (80.8 and 46.2%) than Group 1 (73.9 and 17.4%); however, there were no differences between Group 2 and Group 3 (P > 0.05). The rates of macular hole closure were extremely low in Group 1 and also in eyes with extreme long axial lengths (≥29.0 mm), "severe" chorioretinal atrophy, and posterior staphyloma.
  
  
  CONCLUSIONS
  Pars plana vitrectomy with either TA assistance or ILM peeling was effective for the treatment of highly myopic MHRD. If you peel the ILM, adding TA does not affect closure rates; and if TA is used to visualize the vitreous, ILM peeling may not be necessary in MHRD. There was a lower anatomical success rate in MHRD with extreme long axial lengths, severe chorioretinal atrophy, and posterior staphyloma.
authors.affiliation: Shaanxi Ophthalmic Medical Center, Xi'an No.4 Hospital, Affiliated Guangren Hospital, School of Medicine, Xi'an Jiaotong, University, Xi'an, China. weiyongdoctor@163.com
authors.forename: Yong
authors.initials: Y
authors.lastname: Wei
authors.forename: Ningli
authors.initials: N
authors.lastname: Wang
authors.forename: Zhongqiao
authors.initials: Z
authors.lastname: Zu
authors.forename: Chuncao
authors.initials: C
authors.lastname: Bi
authors.forename: Huaizhou
authors.initials: H
authors.lastname: Wang
authors.forename: Fenghua
authors.initials: F
authors.lastname: Chen
authors.forename: Xingguang
authors.initials: X
authors.lastname: Yang
mesh_terms: D000368:Aged; D016022:Case-Control Studies; D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy / Q000379:methods; D019773:Epiretinal Membrane / Q000601:surgery*; D005260:Female; D005938:Glucocorticoids / Q000627:therapeutic use*; D006801:Humans; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D009216:Myopia / Q000150:complications*; D012163:Retinal Detachment / Q000209:etiology / Q000601:surgery*; D012167:Retinal Perforations / Q000209:etiology / Q000601:surgery*; D014221:Triamcinolone / Q000627:therapeutic use*; D014821:Vitrectomy / Q000379:methods*
chemical_list: D005938:Glucocorticoids; D014221:Triamcinolone